Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease.

Abstract

Previous GWAS studies have reported significant associations between various common SNPs and prostate cancer risk using cases unselected for family history. How these variants influence risk in familial prostate cancer is not well studied. Here, we analyzed 25 previously reported SNPs across 14 loci from prior prostate cancer GWAS. The International Consortium for Prostate Cancer Genetics (ICPCG) previously validated some of these using a family-based association method (FBAT). However, this approach suffered reduced power due to the conditional statistics implemented in FBAT. Here, we use a case-control design with an empirical analysis strategy to analyze the ICPCG resource for association between these 25 SNPs and familial prostate cancer risk. Fourteen sites contributed 12,506 samples (9,560 prostate cancer cases, 3,368 with aggressive disease, and 2,946 controls from 2,283 pedigrees). We performed association analysis with Genie software which accounts for relationships. We analyzed all familial prostate cancer cases and the subset of aggressive cases. For the familial prostate cancer phenotype, 20 of the 25 SNPs were at least nominally associated with prostate cancer and 16 remained significant after multiple testing correction (p ≤ 1E (-3)) occurring on chromosomal bands 6q25, 7p15, 8q24, 10q11, 11q13, 17q12, 17q24, and Xp11. For aggressive disease, 16 of the SNPs had at least nominal evidence and 8 were statistically significant including 2p15. The results indicate that the majority of common, low-risk alleles identified in GWAS studies for all prostate cancer also contribute risk for familial prostate cancer, and that some may contribute risk to aggressive disease.

• Authors: Craig C Teerlink, Stephen N Thibodeau, Shannon K McDonnell, Daniel J Schaid, Antje Rinckleb, Christiane Maier, Walther Vogel, Geraldine Cancel-Tassin, Christophe Egrot, Olivier Cussenot, William D Foulkes, Graham G Giles, John L Hopper, Gianluca Severi, Ros Eeles, Douglas Easton, Zsofia Kote-Jarai, Michelle Guy, Kathleen A Cooney, Anna M Ray, Kimberly A Zuhlke, Ethan M Lange, Liesel M Fitzgerald, Janet L Stanford, Elaine A Ostrander, Kathleen E Wiley, Sarah D Isaacs, Patrick C Walsh, William B Isaacs, Tiina Wahlfors, Teuvo Tammela, Johanna Schleutker, Fredrik Wiklund, Henrik Grönberg, Monica Emanuelsson, John Carpten, Joan Bailey-Wilson, Alice S Whittemore, Ingrid Oakley-Girvan, Chih-Lin Hsieh, William J Catalona, S Lilly Zheng, Guangfu Jin, Lingyi Lu, Jianfeng Xu, International Consortium for Prostate Cancer Genetics, Nicola J Camp, Lisa A Cannon-Albright
• Journal: Human genetics (Hum Genet) Vol. 133 Issue 3 Pg. 347-56 (Mar 2014) ISSN: 1432-1203 [Electronic] Germany
• PMID: 24162621 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Topics

• Alleles
• Case-Control Studies
• Follow-Up Studies
• Genetic Predisposition to Disease
• Genome-Wide Association Study
• Genotype
• Humans
• Male
• Meta-Analysis as Topic
• Pedigree
• Phenotype
• Polymorphism, Single Nucleotide
• Prostatic Neoplasms (genetics)
• Risk Factors